PMID- 14681904
OWN - NLM
STAT- MEDLINE
DCOM- 20040728
LR  - 20220330
IS  - 1552-4841 (Print)
IS  - 1552-4841 (Linking)
VI  - 124B
IP  - 1
DP  - 2004 Jan 1
TI  - Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism 
      in cognitive dysfunctions and therapeutic response to atypical antipsychotics in 
      patients with schizophrenia.
PG  - 1-5
AB  - Molecular components of the dopaminergic system may play an important role in the 
      pathophysiology of schizophrenia. In this study, we investigated the relationship 
      of the Ser9Gly (S/G) polymorphism of the dopamine D3 receptor (DRD3) and the 
      variable number of tandem repeats (VNTR) polymorphism of the dopamine transporter 
      (DAT) with therapeutic response to atypical antipsychotics (clozapine, 
      olanzapine, quetiapine, risperidone) and cognitive functions. No associations 
      were found between the DRD3 and DAT polymorphisms and schizophrenia. The S/S 
      genotype and the S allele were more frequent in the non-responder patients (n = 
      28) than in the group of responders (n = 47) (cut-off: >20-point improvement in 
      Global Assessment of Functioning (GAF) scale). The patients with S/S genotype 
      completed fewer categories and had more perseverative errors in the Wisconsin 
      Card Sorting Test (WCST) compared with the S/G patients. The S/S and S/G patients 
      did not differ in positive and negative symptoms, GAF scores, WCST failure to 
      maintain set, and verbal learning. No differences in symptoms or WCST measures 
      were observed in the patients with different DAT genotypes. These results suggest 
      that the S/S genotype of the DRD3 is associated with worse therapeutic response 
      and more severe executive dysfunctions in patients with schizophrenia.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Szekeres, Gyorgy
AU  - Szekeres G
AD  - Department of Psychiatry, University of Szeged, Szeged, Hungary. 
      szeri@phys.szote.u-szeged.hu
FAU - Keri, Szabolcs
AU  - Keri S
FAU - Juhasz, Anna
AU  - Juhasz A
FAU - Rimanoczy, Agnes
AU  - Rimanoczy A
FAU - Szendi, Istvan
AU  - Szendi I
FAU - Czimmer, Csongor
AU  - Czimmer C
FAU - Janka, Zoltan
AU  - Janka Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the 
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
RN  - 0 (Antipsychotic Agents)
RN  - 0 (DRD3 protein, human)
RN  - 0 (Dibenzothiazepines)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0 (Receptors, Dopamine D3)
RN  - 0 (SLC6A3 protein, human)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - J60AR2IKIC (Clozapine)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Analysis of Variance
MH  - Antipsychotic Agents/*therapeutic use
MH  - Benzodiazepines/therapeutic use
MH  - Clozapine/therapeutic use
MH  - Cognition Disorders/etiology/pathology/*physiopathology
MH  - Dibenzothiazepines/therapeutic use
MH  - Dopamine Plasma Membrane Transport Proteins
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Humans
MH  - Male
MH  - *Membrane Glycoproteins
MH  - Membrane Transport Proteins/*genetics
MH  - Middle Aged
MH  - Minisatellite Repeats/genetics
MH  - Nerve Tissue Proteins/*genetics
MH  - Olanzapine
MH  - *Polymorphism, Genetic
MH  - Quetiapine Fumarate
MH  - Receptors, Dopamine D2/*genetics
MH  - Receptors, Dopamine D3
MH  - Risperidone/therapeutic use
MH  - Schizophrenia/complications/*drug therapy/genetics
EDAT- 2003/12/19 05:00
MHDA- 2004/07/29 05:00
CRDT- 2003/12/19 05:00
PHST- 2003/12/19 05:00 [pubmed]
PHST- 2004/07/29 05:00 [medline]
PHST- 2003/12/19 05:00 [entrez]
AID - 10.1002/ajmg.b.20045 [doi]
PST - ppublish
SO  - Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):1-5. doi: 
      10.1002/ajmg.b.20045.